Entrada Therapeutics (TRDA) Accumulated Depreciation (2020 - 2021)
Entrada Therapeutics (TRDA) posted quarterly Accumulated Depreciation of $1.4 million for Q4 2021, up 275.6% year-over-year from $377000.0 in Q4 2020, and up 34.6% quarter-over-quarter from $1.1 million in Q3 2021.
Powered by 
Analysis
Entrada Therapeutics (TRDA) Accumulated Depreciation (2020 - 2021) Analysis & Trends
Entrada Therapeutics' Accumulated Depreciation history runs 2 years deep, the most recent figure standing at $1.4 million for Q4 2021.
- In Q4 2021, Accumulated Depreciation rose 275.6% year-over-year to $1.4 million; the TTM figure through Dec 2021 stood at $1.4 million (up 275.6% YoY), while the FY2021 annual figure was $1.4 million, up 275.6% from the prior year.
- Accumulated Depreciation for Q4 2021 stood at $1.4 million, up from $1.1 million in the prior quarter.
- The five-year high for Accumulated Depreciation was $1.4 million in Q4 2021, with the low at $377000.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Entrada Therapeutics | 297.03 Mn | 297.03 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 1.42 Mn |
| Sep 30, 2021 | 1.05 Mn |
| Dec 31, 2020 | 377,000.00 |